BIO-key Q1 revenue up 34% to $2.15M, net loss narrows to $(165K); sees Q2 profitability on 65% revenue jump

BIO KEY INTERNATIONAL INC

Q1 2026 revenue $2.15M (+34% YoY); net loss improved to $(165K) from $(737K) in Q1 2025.
Gross margin 82%; cash $2.24M at quarter end; EPS $(0.15) post-reverse split.
Q2 2026 revenue guided ~$2.8M (+65% YoY); expects H1 2026 profitability vs H1 2025 net loss of $(1.9M).
Secured $1.04M license renewal with foreign bank; defense sales surpassed $2M in trailing twelve months.
Shares suspended from Nasdaq, now trading OTC under BKYI; company working to return to Nasdaq.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO KEY INTERNATIONAL INC reported first quarter 2026 results: revenue $2.15M, net income $(165K). Guidance raised.

Period: first quarter 2026
Revenue: $2.15M
Net income: $(165K)
Guidance: raised
Result: reported results

Exact text from the filing

Q1’26 revenues increased 34% to $2.15M vs. Q1’25 and 74% vs. Q4’25 ● Q1’26 net loss improved to $(165K) vs. $(737K) in Q1’25 and $(1.722M) in Q4’25

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-26-017518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.